Stockreport

NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018

NEWLINK GENETICS  (NLNK) 
Last newlink genetics earnings: 2/28 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.linkp.com/investor-relations
PDF AMES, Iowa, May 16, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two Phase 2 studies of indoximod, used in c [Read more]